leisure time -WSS

leisure time

author：hotspot 2025-10-01 02:44:28 - browse：33982

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： In same hospitals, Black patients receive fewer opioids than white patients

WSS

The best solution to the drug shortages problem

30 years of 'Listening to Prozac'

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

How to use technology to prevent future drug shortages

Wegovy trial has doctors encouraged over new possibilities

Naloxone nonprofit donates 200,000 doses after FDA approval

knowledge

leisure time

explore

What does generative AI mean for health care? We asked experts

In same hospitals, Black patients receive fewer opioids than white patients

How one medical school became remarkably diverse

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

State Dept. review finds Biden bears some blame for Afghanistan failures

Rep. Raul Ruiz on the physician shortage and more

New air purifier tech could be key to improving indoor air quality

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

23andMe had bad news about my health. I wish a person had delivered it

Anavex keeps shifting the goalposts in its clinical trials

focus

Wegovy trial has doctors encouraged over new possibilities

FDA panel issues narrow recommendation for Covid vaccine booster doses

Drastic changes should bring profitability, startup health insurers say

FDA investigates CAR

Friends ask where James Watson's attitudes about race came from

Maui's cultural, historic landmarks damaged in the devastating wildfires

focus

leisure time

focus

explore